Trevi Therapeutics’ (TRVI) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a research note published on Thursday morning,Benzinga reports. Needham & Company LLC currently has a $8.00 price target on the stock.

Several other brokerages have also issued reports on TRVI. B. Riley reiterated a “buy” rating and issued a $6.00 price target on shares of Trevi Therapeutics in a report on Monday, October 7th. EF Hutton Acquisition Co. I upgraded Trevi Therapeutics to a “strong-buy” rating in a report on Monday, August 19th. Raymond James initiated coverage on shares of Trevi Therapeutics in a research note on Friday, August 30th. They set an “outperform” rating and a $9.00 price target for the company. Leerink Partners started coverage on shares of Trevi Therapeutics in a research note on Monday, September 9th. They issued an “outperform” rating and a $7.00 price objective on the stock. Finally, Leerink Partnrs raised shares of Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $9.31.

Trevi Therapeutics Trading Up 15.8 %

Trevi Therapeutics stock opened at $4.17 on Thursday. The firm’s fifty day moving average is $2.99 and its 200 day moving average is $2.93. Trevi Therapeutics has a 12-month low of $1.22 and a 12-month high of $4.60.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same quarter in the previous year, the business posted ($0.08) EPS. As a group, equities research analysts predict that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in TRVI. BNP Paribas Financial Markets grew its position in Trevi Therapeutics by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after purchasing an additional 6,764 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new position in shares of Trevi Therapeutics during the 1st quarter worth approximately $47,000. Intech Investment Management LLC purchased a new position in shares of Trevi Therapeutics in the 3rd quarter worth approximately $63,000. Hsbc Holdings PLC bought a new position in shares of Trevi Therapeutics in the second quarter valued at approximately $61,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Trevi Therapeutics during the third quarter valued at approximately $78,000. 95.76% of the stock is owned by institutional investors.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.